##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 155 No. 7 (2025)

Genetically engineered T cell and tumour-infiltrating lymphocyte therapies

Cite this as:
Swiss Med Wkly. 2025;155:4279
Published
24.07.2025

Summary

Haemato-oncology has made significant progress in recent years, particularly through the development of innovative immunotherapeutic approaches such as CAR T cell (chimeric antigen receptor T cell) and tumour-infiltrating lymphocyte therapies. Both methods use the patient’s own immune system to treat cancer, but in different ways. CAR T cell therapy is a form of immunotherapy in which the patient’s own T cells are genetically modified. CAR T cell therapies have proven to be particularly effective in haematological B-cell neoplasms, such as B-cell acute lymphoblastic leukaemia (B-ALL) and B-cell lymphomas, as well as in multiple myeloma. Tumour-infiltrating lymphocyte therapy, on the other hand, exploits the natural ability of T cells to recognise tumour-associated antigens of tumour cells with the T cell receptor. Tumour tissue is taken from the patient then tumour-infiltrating lymphocytes are isolated from it. These tumour-infiltrating lymphocytes are expanded ex vivo to increase their number and activity. This review discusses the principles of these innovative therapies. Both therapies represent significant advances in personalised cancer treatment and offer new hope for our cancer patients.

References

  1. Bicak M, Cimen Bozkus C, Bhardwaj N. Checkpoint therapy in cancer treatment: progress, challenges, and future directions. J Clin Invest. 2024 Sep;134(18):e184846. doi: https://doi.org/10.1172/JCI184846
  2. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 Apr;186(8):1652–69. doi: https://doi.org/10.1016/j.cell.2023.03.006
  3. Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May;2(5):e192535. doi: https://doi.org/10.1001/jamanetworkopen.2019.2535
  4. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018 Jul;379(1):64–73. 10.1056/NEJMra1706169
  5. Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022 Dec;387(23):2113–25. doi: https://doi.org/10.1056/NEJMoa2210233
  6. Thomas ED. Bone marrow transplantation from the personal viewpoint. Int J Hematol. 2005 Feb;81(2):89–93. doi: https://doi.org/10.1532/IJH97.04197
  7. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004 Dec;114(12):1774–81. doi: https://doi.org/10.1172/JCI200422284
  8. Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023 Feb;614(7949):635–48. doi: https://doi.org/10.1038/s41586-023-05707-3
  9. Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al.; ZUMA-7 Investigators; Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul;389(2):148–57. doi: https://doi.org/10.1056/NEJMoa2301665
  10. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar;388(11):1002–14. doi: https://doi.org/10.1056/NEJMoa2213614
  11. Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024 May;31(5):667–86. doi: https://doi.org/10.1038/s41417-024-00750-2
  12. Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 Sep;387(13):1196–206. doi: https://doi.org/10.1056/NEJMoa2209900
  13. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022 Jun;28(6):1189–98. doi: https://doi.org/10.1038/s41591-022-01800-8
  14. Mackensen A, Haanen JB, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023 Nov;29(11):2844–53. doi: https://doi.org/10.1038/s41591-023-02612-0
  15. Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024 Apr;390(14):1290–8. doi: https://doi.org/10.1056/NEJMoa2314390
  16. Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024 May;30(5):1320–9. doi: https://doi.org/10.1038/s41591-024-02893-z
  17. Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 Mar;603(7903):934–41. doi: https://doi.org/10.1038/s41586-022-04489-4
  18. D’Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr;403(10435):1460–71. doi: https://doi.org/10.1016/S0140-6736(24)00319-2
  19. Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021 Apr;13(591):eabe7378. doi: https://doi.org/10.1126/scitranslmed.abe7378
  20. Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 2022 Dec;40(12):1470–1487.e7. doi: https://doi.org/10.1016/j.ccell.2022.11.006
  21. Schett G, Müller F, Taubmann J, Mackensen A, Wang W, Furie RA, et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024 Sep;20(9):531–44. doi: https://doi.org/10.1038/s41584-024-01139-z
  22. Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021 Aug;385(6):567–9. doi: https://doi.org/10.1056/NEJMc2107725
  23. Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124–32. doi: https://doi.org/10.1038/s41591-022-02017-5
  24. Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb;390(8):687–700. doi: https://doi.org/10.1056/NEJMoa2308917
  25. Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024 Jan;63(1):e12–4. doi: https://doi.org/10.1093/rheumatology/kead330
  26. Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA. 2023 Jun;329(24):2154–62. doi: https://doi.org/10.1001/jama.2023.8753
  27. Granit V, Benatar M, Kurtoglu M, Miljković MD, Chahin N, Sahagian G, et al.; MG-001 Study Team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023 Jul;22(7):578–90. doi: https://doi.org/10.1016/S1474-4422(23)00194-1
  28. Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023 Mar;401(10379):815–8. doi: https://doi.org/10.1016/S0140-6736(23)00023-5
  29. Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med (N Y). 2024 Jun;5(6):550–558.e2. doi: https://doi.org/10.1016/j.medj.2024.03.002
  30. Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024 Jul;21(7):501–21. doi: https://doi.org/10.1038/s41571-024-00903-0
  31. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022 Feb;22(2):85–96. doi: https://doi.org/10.1038/s41577-021-00547-6
  32. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al.; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 Feb;386(7):640–54. doi: https://doi.org/10.1056/NEJMoa2116133
  33. Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023 May;141(20):2430–42.
  34. Klobuch S, Seijkens TT, Schumacher TN, Haanen JB. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024 Mar;21(3):173–84. doi: https://doi.org/10.1038/s41571-023-00848-w
  35. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec;319(25):1676–80. doi: https://doi.org/10.1056/NEJM198812223192527
  36. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, et al. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016 Jul;34(20):2389–97. doi: https://doi.org/10.1200/JCO.2016.66.7220
  37. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014 Jan;257(1):56–71. doi: https://doi.org/10.1111/imr.12132
  38. König D, Sandholzer MT, Uzun S, Zingg A, Ritschard R, Thut H, et al. Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes. Cancer Immunol Res. 2024 Jul;12(7):814–21. doi: https://doi.org/10.1158/2326-6066.CIR-23-0757
  39. Schoenfeld AJ, Lee SM, Doger de Spéville B, Gettinger SN, Häfliger S, Sukari A, et al. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discov. 2024 Aug;14(8):1389–402. doi: https://doi.org/10.1158/2159-8290.CD-23-1334
  40. Rohaan MW, van den Berg JH, Kvistborg P, Haanen JB. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer. 2018 Oct;6(1):102. doi: https://doi.org/10.1186/s40425-018-0391-1
  41. Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug;27(8):1410–8. doi: https://doi.org/10.1038/s41591-021-01462-y
  42. Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. J Immunother Cancer. 2023 Nov;11(11):e007784. doi: https://doi.org/10.1136/jitc-2023-007784